Methods and compositions for locally increasing body fat

• US 8,778,981 B2
• Filed: 11/21/2013
• Issued: 07/15/2014
• Est. Priority Date: 11/21/2012
• Status: Expired due to Fees

• Current Assignee: Velakine Therapeutics, Inc.
• Original Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Inventors: Kalayoglu, Murat V., Singer, Michael S.
• Primary Examiner(s): RAO, SAVITHA M
• Application Number:
  US14/086,785
• Publication Number:
  US 20140142075A1
• Time in Patent Office: 236 Days
• Field of Search: 514/369, 514/342, 514/256, 514/299, 514/367, 514/370, 548/183
• US Class Current: 514/369
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 47/14 Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 8/34 Alcohols
• CPC Class Codes: A61K 8/345 containing more than one hydroxy group
• CPC Class Codes: A61K 8/361 Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
• CPC Class Codes: A61K 8/37 Esters of carboxylic acids
• CPC Class Codes: A61K 8/49 containing heterocyclic compounds
• CPC Class Codes: A61K 8/4926 having six membered rings
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/00 : Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 : Antihyperlipidemics
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/18 : for HIV
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61Q 19/08 : Anti-ageing preparations

Abstract

Provided are methods for increasing fat locally in a body of a subject in need thereof comprising percutaneously administering to the subcutaneous fat of the subject a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, optionally delivered as a composition comprising a pharmaceutically acceptable carrier, as described herein. In certain embodiments, the pharmaceutically acceptable carrier comprises a percutaneous carrier, as described herein. Further provided are compositions comprising a thiazolidinedione or an orexigenic compound, or a pharmaceutically acceptable salt or prodrug thereof, for use according to the invention.

Claims

1. A method for increasing subcutaneous fat locally in a body of a subject in need thereof, the method comprising topically administering to the skin of the subject a thiazolidinedione selected from the group consisting of:

2. The method of claim 1, wherein the subject suffers from a subcutaneous fat deficiency.

3. The method of claim 2, wherein the subcutaneous fat deficiency is associated with a metabolic disorder.

4. The method of claim 2, wherein the subcutaneous fat deficiency is acquired.

5. The method of claim 4, wherein the acquired subcutaneous fat deficiency is HIV-associated lipodystrophy, lipidema, acquired partial lipodystrophy, acquired generalized lipodystrophy, Parry-Romberg syndrome, juvenile dermatomyositis, centrifugal abdominal lipodystrophy, lipoatrophia annularis, or localized lipodystrophy.

6. The method of claim 2, wherein the subcutaneous fat deficiency is caused by a medication, surgery, or an injury.

7. The method of claim 1, wherein the subject suffers from wrinkles of the skin.

8. The method of claim 1, wherein the subject suffers from dissatisfaction with the size or contour of a body part.

9. The method of claim 8, wherein the body part is the face, forehead, periorbital region of the face, cheeks, chin, lips, breast, limbs, hands, trunk, hips, or buttocks.

10. The method of claim 1, wherein the subject has transplanted fat.

11. The method of claim 1, wherein the thiazolidinedione is rosiglitazone or a pharmaceutically acceptable salt thereof.

12. The method of claim 11, wherein the rosiglitazone is administered in a composition at a concentration between about 0.1 percent and about 2 percent by weight.

13. The method of claim 1, wherein the percutaneous carrier comprises oleic acid.

14. The method of claim 13, wherein the oleic acid is administered in a composition at a concentration between about 1 percent and about 5 percent by weight.

15. The method of claim 1, wherein the percutaneous carrier comprises propylene glycol.

16. The method of claim 15, wherein the propylene glycol is administered in a composition at a concentration between about 20 percent and about 40 percent by weight.

17. The method of claim 1, wherein the percutaneous carrier comprises propylene glycol and oleic acid.

18. The method of claim 1, wherein the fat is locally increased by at least 10 percent, at least 20 percent, at least 30 percent, or at least 40 percent compared to control.

19. The method of claim 1, wherein increasing fat locally occurs locally on the face, breast, limbs, hands, trunk, hips, or buttocks.

20. The method of claim 1, wherein the administering is three times a day, twice a day, once a day, every other day, or every third day.